We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
339-P: Glycemic Variability Assessed by CGM Relates to Hypoglycemia across the Lifespan in Type 1 Diabetes (T1D).
- Authors
COOPER, BLAKE A.; MILLER, KELLEE; LAFFEL, LORI M.
- Abstract
Aim: CGM can predict and reduce hypoglycemia in persons with T1D by providing real-time (RT) glucose levels and trend arrows. Using CGM data, one can assess glycemic variability with coefficient of variation for glucose (CV, glucose SD/mean x 100%). Current guidelines target a CV ≤36, given its association with reduced occurrence of hypoglycemia. Methods: As glycemic levels fluctuate across the lifespan, we aimed to evaluate associations between CV and hypoglycemia (time below range [TBR] <70 and <54 mg/dL) in 3 US studies evaluating CGM in persons with T1D (SENCE [N=143, 2-6y]/CITY [N=152, 14-24y]/WISDM [N=203, 60-86y]). Mean hours of CGM for each participant was over 300 hours at baseline and over 500 hours at the 12-month follow up period. Analyses accounted for non-normal distributions of TBR. Results: Across all studies, higher CV was associated with more TBR (all p<.0001), with higher correlations in younger cohorts (Table). When CV>36 vs. CV≤36, TBR was higher in all 3 cohorts (p<.0001). From ~2 weeks of baseline, masked CGM data collected before starting RT-CGM to 12 months after RT-CGM initiation, proportion achieving CV≤36 increased from 13 to 31%, 21 to 35%, and 20 to 55% in SENCE, CITY, and WISDM, respectively, (all p≤.01). Summary: CGM use helped to reduce CV and TBR over time. These 3 studies affirm that glycemic variability (CV) relates to hypoglycemia across the lifespan in T1D. Disclosure: B. A. Cooper: Speaker's Bureau; Self; Regeneron Pharmaceuticals Inc. K. Miller: Other Relationship; Self; Dexcom, Inc., Tandem Diabetes Care, Research Support; Self; JDRF, Leona M. and Harry B. Helmsley Charitable Trust. L. M. Laffel: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompe, Insulogic LLC, Janssen Pharmaceuticals, Inc., Laxmi Therapeutic Devices, LifeScan, Lilly Diabetes, Medtronic, Provention Bio, Inc. Funding: National Institute of Diabetes and Digestive and Kidney Diseases (P30DK036836); The Leona M. and Harry B. Helmsley Charitable Trust
- Publication
Diabetes, 2021, Vol 70, pN.PAG
- ISSN
0012-1797
- Publication type
Article
- DOI
10.2337/db21-339-P